Citigroup
PRLD icon

Citigroup’s Prelude Therapeutics PRLD Stock Holding History

Citigroup’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17 Buy
5
+4
+400% +$10 ﹤0.01% 5703
2025
Q4 		$3 Sell
1
-5,974
-100% -$10.1K ﹤0.01% 5908
2025
Q3 		$8.6K Buy
5,975
+1,257
+27% +$1.26K ﹤0.01% 5073
2025
Q2 		$3.82K Sell
4,718
-4,582
-49% -$3.97K ﹤0.01% 5310
2025
Q1 		$7.14K Sell
9,300
-915
-9% -$854 ﹤0.01% 5242
2024
Q4 		$13K Buy
10,215
+560
+6% +$743 ﹤0.01% 5338
2024
Q3 		$20K Buy
9,655
+6,641
+220% +$30.8K ﹤0.01% 5189
2024
Q2 		$11.5K Buy
3,014
+205
+7% +$834 ﹤0.01% 5114
2024
Q1 		$13.3K Buy
2,809
+682
+32% +$2.65K ﹤0.01% 5133
2023
Q4 		$9.08K Buy
2,127
+1,601
+304% +$4.87K ﹤0.01% 5216
2023
Q3 		$1.63K Sell
526
-3,315
-86% -$12.4K ﹤0.01% 5016
2023
Q2 		$17.3K Sell
3,841
-66,926
-95% -$400K ﹤0.01% 4990
2023
Q1 		$403K Buy
70,767
+10,695
+18% +$65.2K ﹤0.01% 3272
2022
Q4 		$363K Buy
60,072
+51,540
+604% +$330K ﹤0.01% 3379
2022
Q3 		$56K Buy
8,532
+7,691
+915% +$51.8K ﹤0.01% 4341
2022
Q2 		$4K Sell
841
-878
-51% -$4.47K ﹤0.01% 5704
2022
Q1 		$12K Sell
1,719
-2,359
-58% -$21.6K ﹤0.01% 5439
2021
Q4 		$51K Sell
4,078
-20,190
-83% -$328K ﹤0.01% 5059
2021
Q3 		$758K Sell
24,268
-51,355
-68% -$1.66M ﹤0.01% 3300
2021
Q2 		$2.17M Buy
75,623
+15,026
+25% +$535K ﹤0.01% 2605
2021
Q1 		$2.63M Buy
60,597
+58,866
+3,401% +$3.91M ﹤0.01% 2306
2020
Q4 		$124K Buy
+1,731
New +$86.1K ﹤0.01% 5365

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Citigroup's PRLD Position: Q1 2026 in Review

Citigroup increased its Prelude Therapeutics (PRLD) stake by 400% in Q1 2026, buying an estimated $10 and bringing the position to 5 shares worth $17. The position accounts for ﹤0.01% of the portfolio, ranked #5703.

Citigroup first reported a position in PRLD in Q4 2020 and has held it in 22 quarters since. The position peaked at $2.63M in Q1 2021. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Citigroup held 5 shares of Prelude Therapeutics worth $17 as of Q1 2026.
  • Citigroup bought 4 Prelude Therapeutics shares in Q1 2026, an estimated $10.
  • Prelude Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5703 holding.
  • Citigroup first reported a position in Prelude Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Citigroup's Prelude Therapeutics position peaked at $2.63M in Q1 2021.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.